(Q53359316)

English

A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

phase II clinical trial

0 references

Branimir Ivan Sikic

10

object named as

Branimir I Sikic

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

Lynn C. Hartmann

5

object named as

Lynn Hartmann

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

Ranjana H. Advani

1

object named as

Ranjana Advani

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

author name string

Prema Peethambaram

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

Bert L Lum

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

George A Fisher

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

Harry J Long

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

Joanne Halsey

7

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

Jon T Holmlund

8

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

Andrew Dorr

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

language of work or name

0 references

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

100

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

321-326

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

The potential of protein kinase C as a target for anticancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11909

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of protein kinase C and role in cancer biology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11909

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11909

7 January 2021

based on heuristic

inferred from DOI database lookup

Progress in antisense oligonucleotide therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11909

7 January 2021

based on heuristic

inferred from DOI database lookup

Reliability and validity of the functional assessment of cancer therapy-ovarian.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11909

7 January 2021

based on heuristic

inferred from DOI database lookup

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11909

7 January 2021

based on heuristic

inferred from DOI database lookup

Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11909

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11909

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/14716767

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53359316&oldid=1989379526"